Skip to main content

Table 3 Health impacts, annual costs and benefits from reducing chlordecone exposures in Guadeloupe (Without threshold)

From: Public health and chronic low chlordecone exposures in Guadeloupe; Part 2: Health impacts, and benefits of prevention

Health outcome Main source of variation Population at risk Period of exposure measurement n Impact (mean estimate) CI low (€2006) CI mean (€2006) CI high (€2006) Proportion (mean estimate)
Liver cancer Conversion from ingestion dose to blood chlordecone All <2003 436 968 5.4 8 821 000 13 129 000 26 874 000 34 %
≥2003 458 465 2.0 3 274 000 4 873 000 9 974 000 21 %
Annual benefit   −3.4 5 547 000 8 256 000 16 900 000 56 %
Prostate cancer IC95% of RR Men > 44 years <2003 72 566 2.8 1 405 000 5 152 000 10 572 000 13 %
≥2003 76 049 1.0 490 000 1 797 000 3 687 000 8 %
Annual benefit   −1.8 915 000 3 355 000 6 885 000 23 %
Renal dysfunction BMD10-HED Women <2003 227 417 0.10 27 000 308 000 769 000 0.80 %
≥2003 239 470 0.04 11 000 128 000 320 000 0.54 %
Annual benefit   −0.06 16 000 180 000 449 000 1.23 %
Cognitive development Equivalence between QI point and ASQ point Male new born <2003 3 747 1 173 3 949 000 19 745 000 39 489 000 52 %
≥2003 3 929 1 003 3 377 000 16 887 000 33 773 000 71 %
Annual benefit   −168 572 000 2 858 000 5 716 000 20 %
Total    <2003    14 202 000 38 334 000 77 704 000 100 %
≥2003    7 152 000 23 685 000 47 754 000 100 %
Annual benefit    7 050 000 14 649 000 29 950 000 100 %
  1. n = population, 2002 census data for the first period of time and 2006 census data for second period. Impacts are expressed in number of death, except for cognitive development where the impacts are expressed in QI point lost. CI = Cost of Impacts (= DALY * VOLY)
  2. Impact is the number of cases (Eq.3), except IQ points for Cognitive development